- Home
- ADI vs LLY Comparison
ADI vs LLY Comparison
Compare ADI & LLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADI | LLY |
|---|---|---|
| Founded | 1965 | 1876 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3B | 950.7B |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ADI | LLY |
|---|---|---|
| Price | $310.85 | $984.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 19 |
| Target Price | $381.70 | ★ $1,174.53 |
| AVG Volume (30 Days) | ★ 3.8M | 2.2M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 1.42% | 0.70% |
| EPS Growth | 39.02 | ★ 95.99 |
| EPS | 1.69 | ★ 22.95 |
| Revenue | $6,200,942,000.00 | ★ $65,179,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.86 | $16.26 |
| P/E Ratio | $183.93 | ★ $43.05 |
| Revenue Growth | 21.41 | ★ 44.70 |
| 52 Week Low | $158.65 | $623.78 |
| 52 Week High | $363.20 | $1,133.95 |
Technical Indicators
Market Signals| Indicator | ADI | LLY |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 43.20 |
| Support Level | $223.69 | $978.77 |
| Resistance Level | $363.20 | $1,102.49 |
| Average True Range (ATR) | 8.30 | 23.87 |
| MACD | -5.63 | -2.25 |
| Stochastic Oscillator | 12.27 | 24.62 |
Price Performance
Historical ComparisonAbout ADI Analog Devices Inc.
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.
About LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.